Ciforadenant

Evidence outlook · lead readout

NCT04280328 · Multiple Myeloma

The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.

NCT04280328: All participants received the same ciforadenant-daratumumab combination with no placebo or comparator arm and no blinding, so the study cannot isolate how much of any benefit came from ciforadenant itself. The primary goals were safety and dose-limiting toxicity, and results have not been posted.